Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping

Julia D. Wulfkuhle¹, Daniela Berg², Claudia Wolff², Rupert Langer², Kai Tran², Julie Illi⁴, Virginia Eschina¹, Mariaelena Pierobon¹, Jianghong Deng¹, Angela DeMichele⁵, Axel Walch⁶, Holger Bronger³, Ingrid Becker², Christine Waldo², Heinz Höffer², Laura Esserman⁴ on behalf of the I-SPY 1 TRIAL Investigators, Lance A. Liotta¹, Karl-Friedrich Becker², and Emanuel F. Petricoin III¹

Abstract

**Purpose:** Targeting of the HER2 protein in human breast cancer represents a major advance in oncology but relies on measurements of total HER2 protein and not HER2 signaling network activation. We used reverse-phase protein microarrays (RPMA) to measure total and phosphorylated HER2 in the context of HER family signaling to understand correlations between phosphorylated and total levels of HER2 and downstream signaling activity.

**Experimental Design:** Three independent study sets, comprising a total of 415 individual patient samples from flash-frozen core biopsy samples and formalin-fixed and paraffin-embedded (FFPE) surgical and core samples, were analyzed via RPMA. The phosphorylation and total levels of the HER receptor family proteins and downstream signaling molecules were measured in laser capture micro-dissected (LCM) enriched tumor epithelium from 127 frozen pretreatment core biopsy samples and whole-tissue lysates from 288 FFPE samples and these results were compared with FISH and immunohistochemistry (IHC).

**Results:** RPMA measurements of total HER2 were highly concordant (>90% all sets) with FISH and/or IHC data, as was phosphorylation of HER2 in the FISH/IHC population. Phosphorylation analysis of HER family signaling identified HER2 activation in some FISH/IHC tumors and, identical to that seen with FISH/IHC tumors, the HER2 activation was concordant with EGF receptor (EGFR) and HER3 phosphorylation and downstream signaling endpoint activation.

**Conclusions:** Molecular profiling of HER2 signaling of a large cohort of human breast cancer specimens using a quantiative and sensitive functional pathway activation mapping technique reveals IHC/FISH/ pHER2 tumors with HER2 pathway activation independent of total HER2 levels and functional signaling through HER3 and EGFR. *Clin Cancer Res; 18(23): 6426–35. ©2012 AACR.*

**Introduction**

The expression of HER family receptor tyrosine kinases has major biologic impact on the pathogenesis of many solid tumors and is an important driving component of signal transduction networks that are deregulated in many cancers (1–3). Trastuzumab therapy offers significant disease-free and overall survival advantages in the metastatic as well as adjuvant settings for patients with HER2-overexpressing breast cancer (4–7). However, recent findings suggest that the benefit of adjuvant trastuzumab may not be limited to patients with HER2 gene amplification (8). Hence, there is an emerging need for new additional diagnostic tests that allow the identification of new breast cancer patient subgroups that may also benefit from HER2-directed therapy.

Currently, HER2 status is routinely determined by immunohistochemistry (IHC), often with additional FISH to verify equivocal IHC results (9, 10). Although IHC is the predominant method for assessing HER2, this assay could produce false-positive or -negative outcomes due to...
Translational Relevance
The identification and characterization of HER2-based protein signaling activation in breast tumors would be of critical importance in the clinical management of a significant number of patients with breast cancer. Using a quantitative, highly sensitive protein array assay, we identified a subgroup of immunohistochemistry (IHC) and FISH patients with HER2-negative breast cancer with levels of activated/phosphorylated HER2 comparable with IHC and FISH HER2-positive tumors that was accompanied by coactivation of HER2-binding partners as well as downstream pathway targets. This group of patients was not identified by current clinically approved tests for HER2 and is currently excluded from trastuzumab treatment. Analysis of the phosphorylation/activation levels of receptor tyrosine kinases, along with the analysis of activation of the linked downstream signal transduction network, can potentially identify new patient cohorts that could benefit from molecular targeted inhibitors, and, thus, functional signaling analysis may provide new opportunities for personalized therapy if these measurements prove clinically useful.

Interoperator variability (11–17). Moreover, IHC and FISH do not provide a quantitative measurement of total HER2 protein levels, nor do they provide data reflecting the activation status of the HER2 protein or the downstream signaling network itself, both of which may limit their effectiveness in patient selection for HER2-targeted therapeutics. Several research groups have reported that the activation/phosphorylation status of HER2 protein provides significant information on breast cancer survival as compared with total HER2 (18–22). In this context, the reverse-phase protein microarray (RPMA) represents a powerful tool for measuring and mapping the protein signaling architecture from clinical samples, allowing both relative and absolute protein quantifications (23, 24).

We used RPMA analysis and assessed its determination of HER2 expression and activation in formalin-fixed and paraffin-embedded (FFPE) and frozen breast cancer tissue samples. We evaluated these study sets in independent laboratories and examined the relationship between a quantitative assay (RPMA) that measures both total and phosphorylation levels of HER2 and downstream HER family receptor–driven signaling with HER2 levels as measured by U.S. Food and Drug Administration (FDA)-approved assays such as IHC and FISH. This analysis provides a starting point to understand the relationships between the quantitative measurement of important receptor tyrosine kinase levels in clinical samples, their relative levels of activation, and measurements of downstream signaling.

Materials and Methods
Patient samples and tissue processing
For the analysis of frozen tissue specimens, a total of 127 pretreatment breast cancer biopsy specimens collected in the ISPY-1 TRIAL (CALGB 150007/150012, ACRIN 6657) were subjected to laser capture microdissection (LCM) to enrich for tumor epithelium as described (25, 26). All patients provided Institutional Review Board–approved informed consent before specimen collection. For both datasets (frozen and FFPE tissue), central laboratory measurements of HER2 status (central IHC and/or FISH) were used for comparisons (Table 1). HercepTest (Dako) was used for IHC measurements and Pathvysion (Abbott Molecular) was used for FISH measurements of HER2 status in FFPE material. The anti-HER2 antibody (clone CB11, 1:100 dilution; Biogenex) and the Tricolor HER2/TopoII/CEP17 Probe Kit (Abbott Molecular) were used for central IHC and FISH measurements in the frozen tissue samples, respectively. For the frozen tumor study set, a single pathologist was responsible for all IHC and FISH determinants. For the FFPE analysis, each tissue sample was reviewed by 2 independent pathologists.

Table 1. HER2 measurements for patients in FFPE and frozen tissue study sets

<table>
<thead>
<tr>
<th>HER2 status FFPE specimens</th>
<th>IHC (IHC = 0; IHC = 1+)</th>
<th>IHC = 2+/FISH</th>
<th>IHC = 3+</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical specimen training set, n = 73</td>
<td>57 (78%)</td>
<td>10 (14%)</td>
<td>6 (8%)</td>
</tr>
<tr>
<td>Surgical specimen validation set, n = 125</td>
<td>83 (66%)</td>
<td>15 (12%)</td>
<td>27 (22%)</td>
</tr>
<tr>
<td>Core biopsy training set, n = 31</td>
<td>18 (58%)</td>
<td>2 (6%)</td>
<td>11 (36%)</td>
</tr>
<tr>
<td>Core biopsy validation set, n = 59</td>
<td>36 (61%)</td>
<td>6 (10%)</td>
<td>17 (29%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HER2 status frozen specimens</th>
<th>IHC</th>
<th>IHC indeterminate</th>
<th>FISH</th>
<th>FISH borderline</th>
<th>FISH +</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frozen microdissected biopsy set, n = 127</td>
<td>96 (76%)</td>
<td>2 (2%)</td>
<td>28 (22%)</td>
<td>43 (70%)</td>
<td>2 (3%)</td>
</tr>
</tbody>
</table>

(a) FISH data available for n = 62 cases; HER2 IHC data available for n = 126 cases; 1 case between the 2 datasets is nonoverlapping.
A total of 288 FFPE breast cancer samples diagnosed between 2000 and 2010 were included in this study (198 surgical specimens and 90 core biopsies). These were further divided into training sets (73 and 31, respectively) and validation sets (125 and 59, respectively). Protein extraction was conducted as described (27, 28). Only sections composed of at least 85% tumor cells were analyzed. This investigation was approved by the Human Investigations Committee of the Technical University of Munich, Munich, Germany (project number: 2056/08). All patients gave informed consent.

Array printing and analysis
RPMA printing and analysis for the frozen tissue specimens was conducted as described (25, 26). For the FFPE tissue study, RPMAs were printed, stained, and analyzed as described (29). Total protein levels were assessed in each sample by staining with Sypro Ruby Protein Blot Stain (Invitrogen) according to manufacturer’s instructions for both datasets. Antibody staining intensities were quantified using the MicroVigene v3.5.0.0 Software Package (Vigenetech).

Array immunostaining
HER-related signaling pathway activation in tumor cells was evaluated by staining the arrays with various antibodies targeting key proteins in the HER signal transduction cascade [HER2, pHER2(Y1248), pHER3(Y1289), pEGFR (Y1068), pEGFR(Y1148), pEGFR(Y1173), pEGFR(Y992), pSHC(Y317), pFAK(Y576/Y577), and pSTAT5(Y694)]. Primary antibody dilutions and distributors are listed in Supplementary Table S1. Before use on RPMAs, antibody specificity was confirmed by Western blot analyses as previously described (26, 30).

Quantification of HER2 protein expression by RPMA
For the quantification of HER2 protein carried out for FFPE specimens, purified recombinant HER2 protein (8.8 pg/nL start concentration; #PKSP011; Biaffin) was printed alongside the patient samples in a 6-point dilution curve. A signal intensity versus concentration plot was obtained, and HER2 concentrations were determined for each sample by interpolation of the array signal intensity to this standard concentration curve as previously described (30).

Western blotting
Microdissected tumor epithelial cells from pretreatment specimens of selected patients were lysed in SDS sample buffer and resolved by 4% to 20% gradient Tris-Glycine PAGE (Invitrogen), transferred to polyvinylidene difluoride membrane, and probed with pHER2(Y1248) and β-actin antibodies (Cell Signaling; Supplementary Table S1).

Unsupervised hierarchical clustering and statistical analysis
Unsupervised hierarchical clustering of the FFPE dataset was conducted using Cluster and Tree View software (31). Subsequent to log transformation and center to median correction, average hierarchical clustering was conducted. Cluster mapping for frozen tissue data was conducted using the Ward method for 2-way unsupervised hierarchical clustering in JMP v5.1 (SAS Institute). Receiver operator characteristic (ROC) analysis for determining positive RPMA staining thresholds for total and pHER2 in frozen LCM tissues was conducted in JMP v5.1. T-tests, and Wilcoxon rank-sum tests and ANOVA analyses were conducted using R v2.13.2. GraphPad Prism v5.02 (GraphPad Software) was used to generate graphs.

Results
We first sought to understand the concordance of our total HER2 measurements in frozen tumor tissues by RPMA with current FDA-approved IHC and FISH methods. Table 1 shows the HER2 status distributions for the frozen tissue specimens based on central IHC and FISH measurements of HER2 status in the I-SPY 1 TRIAL. About 22% of these cases were HER2-positive (HER2+) by central IHC (28 of 126) and 27% (17 of 62) were HER2+ by central FISH analysis (Table 1), which correlates well with rates of HER2 overexpression/amplification observed in the general population (32, 33). A threshold level of relative staining intensity for total HER2 protein by RPMA analysis was selected on the basis of ROC analysis, which minimized false-negative and false-positive results when compared with IHC- or FISH-based populations (Fig. 1A). An overall concordance of 95% with central FISH measurements and 94% with central IHC measurements was observed. These data show that RPMA-based continuous variable measurements of total HER2 protein levels in frozen tissues have excellent concordance with traditional IHC and FISH assessments.

We next used RPMA analysis to measure levels of phospho-HER2(Y1248) (pHER2) protein in our frozen sample set to determine total HER2 and pHER2 protein correlations as well as concordance between pHER2 and IHC- and FISH-based HER2 assessments. In a similar manner to the threshold intensity determination for total HER2, we again used ROC analysis to determine an optimal threshold value for pHER2 positivity in the context of the IHC and FISH data. In this study set, 82% (14 of 17) of FISH+ tumors and 79% (22 of 28) of the IHC+ tumors exhibited above-threshold relative levels of pHER2 expression, suggesting that the majority of the HER2+ tumors in the frozen study set also exhibited activation of the receptor (Fig. 1B). We also found that a subset of the HER2-negative (HER2−) tumors, 16% (7 of 44) and 8% (8 of 96) of the FISH− and IHC− tumors, respectively, showed pHER2 levels that were above threshold (Fig. 1B). All but one of the 8 HER2 IHC−/pHER2+ tumors were also central FISH+. The remaining patient had central IHC data only (IHC−) due to a larger central IHC dataset than FISH for the frozen tissue set. We were able to confirm our pHER2 RPMA relative measurements from frozen tumors in a small subset of cases by immunoblotting (Fig. 1C). These results provide evidence for activation of the HER2 receptor in the absence of HER2 overexpression (Fig. 1B), with HER2 activation levels as high (as a population) as IHC/FISH+ patients.
FFPE tissues are used in hospitals worldwide for diagnostic determination of HER2 expression. Therefore, we wanted to determine whether the small HER2+/pHER2+ subpopulation of patients found in frozen tumors could also be found in FFPE tissues. We identified an independent study set of 288 FFPE specimens which included both core biopsies (n = 90) and surgical specimens (n = 198). Overall, 29% (58 of 198) of the FFPE surgical specimen population was determined to be HER2+ by a 3+ IHC score or a 2+ IHC score and a FISH/CEP17 ratio >2.2 (Table 1). In the core biopsy set of FFPE specimens (n = 90), 40% were HER2+ (36 of 90; Table 1). Both of these figures trended slightly higher than estimates for HER2 positivity in the general population of breast cancers (15%–25%; refs. 32, 33). Using RPMA, we assessed HER2 protein concentration in each FFPE patient sample. Array-based HER2 concentration thresholds were established for training sets of surgical specimens (n = 73; HER2 threshold: 12 pg HER2/ng protein) and core biopsies (n = 31; HER2 threshold: 7 pg HER2/ng protein) separately, to optimally distinguish
IHC+ (HER2 IHC = 2+/FISH+; IHC = 3+) from IHC−
(HER2 IHC = 0 or 1++; IHC = 2+/FISH−) tumor samples in
each set. In FFPE tissues, IHC- and RPMA-based HER2
assessment showed a concordance of 96% for surgical and
84% for core biopsy training specimens (Fig. 2A and B).
Application of these RPMA-derived thresholds for total
HER2 in the surgical validation set revealed an overall
concordance between RPMA and IHC of 92% (Fig. 2A and
B). All surgical samples in this set determined as HER2−
by IHC were also classified as HER2− by RPMA, and 8% (10 of
125) of IHC+ samples were determined as HER2− by RPMA.
HER2 determination in the core biopsy validation set
showed an overall concordance of 93%. Only 3 of 59
(5%) samples that were scored HER2+ by IHC were negative
using RPMA, and 1 of 59 (2%) samples classified negative
by IHC showed a positive RPMA HER2 status (Fig. 2A and
B). Assessment of pHER2 levels in the surgical validation
study set revealed pHER2 expression in 46% (17 of 37) of
the IHC/FISH+ HER2 cases and in 26.5% (22 of 83) of the
IHC/FISH− subset of samples (Fig. 2C). While the range of
pHER2 values in the FISH− and FISH+ group were nearly
identical, there was a statistically significant difference in

Figure 2. Correlation of RPMA measurements of HER2 and
pHER2 protein levels with IHC and FISH results for FFPE breast tumor
tissue specimens and identification
of a HER2+pHER2 subpopulation of tumors. A and B,
HER2 concentration thresholds optimally distinguishing HER2
IHC− (HER2 IHC score 3++; 2+/FISH−) from HER2 IHC− (HER2 IHC
score 0; 1++; 2+/FISH−) tumor samples were established within
training sets for FFPE surgical specimens (A, left; HER2
concentration threshold 12 pg
HER2/ng protein), as well as core
biopsies (B, left; HER2
concentration threshold 7 pg
HER2/ng protein). Threshold
values were validated using
independent tissue samples for
each study set (right). Thresholds
for positive and negative samples
are marked by horizontal dashed
lines. C, pHER2 relative intensity
values measured by RPMA are
plotted against HER2 IHC status
for the FFPE surgical validation
study set. A tentative threshold
intensity value of 1,000 RU is
indicated by a dashed line. RU,
relative units.
HER2 Signaling Activation in IHC/FISH-Negative Breast Tumors

Figure 3. Coactivation of various HER family receptors with activation of HER2. Unsupervised hierarchical clustering of various activated HER family relative expression levels in FFPE surgical validation specimens (A) or frozen microdissected breast tumor tissues (B). Green case labels indicate IHC+/FISH−, black indicate IHC+/FISH+, and red indicate IHC+/FISH borderline tumors (horizontal axis). Endpoints examined are clustered on the vertical axis. Black arrows indicate IHC+/FISH+/pHER2 tumors. Within the heatmaps, red color represents higher levels of relative activity/expression, black represents intermediate levels, and green represents lower levels of relative activity/expression.

The median values (664 vs. 986 relative units, respectively) between the 2 populations (P = 0.024 by χ² testing). These data successfully confirm the presence of a similar HER2+/pHER2+ subpopulation of samples in our FFPE study set. To more fully validate the concordance between HER2 and pHER2 levels in the FFPE set, tumor cells were independently lysed from 3 sequential FFPE sections and printed to generate 3 separate lysates (one from each section) on 2 separate sets of arrays and then probed for total HER2 and phospho-HER2 (Y1248). The results (Supplementary Fig. S2) clearly show excellent inter- and intra-array reproducibility of the HER2 and pHER2 FFPE data. The pHER2 measurements obtained by RPMA in the frozen and FFPE samples were generated by 2 independent laboratories at different times, using different instrumentation and methods. While the data gathered can be compared within an individual study set, in keeping with other immunohasays, the absence of bridging cases and controls between the study sets and differences in operating conditions and procedures prevented the direct comparison of data between study sets as there are scalar differences in the data output.

On the basis of these results, we explored whether activated/phosphorylated HER2, regardless of IHC/FISH status, produced a functional signal through the known dimerization-mediated phosphorylation of other HER family members. Unsupervised hierarchical clustering of the FFPE surgical validation study set revealed a subgroup of mostly IHC+/FISH− patients characterized by low relative expression of total HER2 but higher relative levels of pHER2 and pHER3 (Fig. 3A, inset). The statistically confirmed correlation of pHER2 and pHER3 (Spearman correlation coefficient r = 0.705, P = 0.0003) suggests that HER-based signaling in this subgroup of HER2-low tumors may occur via heterodimerization between HER2 and HER3 receptor molecules. Clustering analysis of the frozen microdissected tissues with known IHC/FISH status revealed that the IHC+/FISH+/pHER2+ cases (Fig. 3B, black arrows) often showed concomitant high relative activation of EGFR at various sites compared with the IHC+/FISH−/pHER2− population (Fig. 3B). Specifically, the phosphorylation levels of pHER2(Y1248), pEGFR(Y1173), and pEGFR(Y1148) were elevated (P = 0.00002, 0.01, and 0.07, respectively) in the IHC+/FISH−/pHER2− population compared with the IHC+/FISH+ cohort. In contrast, with the IHC+/FISH+/pHER2− group, the IHC+/FISH+/pHER2+ cohort exhibited coactivation of HER2, EGFR, and HER3 [P = 0.00007 for pHER2(Y1248); P = 0.00002 for pEGFR(Y1092); P = 0.02 for pEGFR(Y1173); and P = 0.004 for pHER3(Y1289)].

We also looked for further evidence of intact HER2-directed signaling in our HER2+/pHER2+ patients. For our frozen LCM study set, in addition to HER2 receptor family activation analysis, we also measured phosphorylation of SHC, STAT5, and FAK, which are downstream cytoplasmic signaling molecules known to be linked to HER2 signaling. We used central IHC data to represent HER2 status in this analysis due to sample size considerations and its near-complete redundancy with central FISH results available for this study set. As shown in Fig. 4A, the level of phosphorylation of each of the signaling proteins was statistically indistinguishable between the IHC+/pHER2+ cohort and the IHC+/pHER2+ group. Conversely, the IHC+/pHER2− group had statistically different and lower activation of these molecules (Fig. 4A). These data suggest that functional HER2 signaling occurs in the IHC+/pHER2+ subpopulation of samples.

Discussion

Currently, IHC and FISH are most commonly used for HER2 assessment and the selection of patients for
Our independent analyses of both frozen and FFPE tissues revealed a population of HER2 tumors that exhibit levels of pHER2 similar to that of HER2 tumors. While the use of these different sets precluded a direct comparison between laboratories and tissue sets, the novel identification of a cohort of women with HER2 breast cancer exhibiting HER2-activated signaling architecture was seen systemically across laboratories, cohorts, and tissue input. This subpopulation of HER2 tumors represents a group of patients who could possibly benefit from treatment with HER2-targeted therapies such as trastuzumab but would not be identified with IHC or FISH testing. Previous studies using a sensitive, but experimental immunoassay for HER2 and pHER2 measurement also found evidence of HER2 phosphorylation in a HER2 group of tumors, but their HER2 status determinations were not correlated back to approved FISH or IHC assays (18).

We observed much larger percentages of FISH or IHC tumors expressing high levels of pHER2 in our frozen, microdissected tissues than in the FFPE study set, with approximately 80% of the HER2 frozen tumors also containing high relative amounts of pHER2. One possible explanation for this is that the LCM process, which enriches for tumor cells, allows for activated HER2 receptor molecules to be more readily detected within a more homogeneous background. However, the FFPE tissue study set was selected on the basis of highly abundant tumor cells. Because formalin penetrates tissue very slowly (~0.1 mm/h; ref. 36), an alternative explanation for the reduced HER2 phosphorylation in the HER2 FFPE tissue is the loss or degradation of phosphate moieties during the fixation process (37–39) and indicates that pHER2 may be more reliably measured in frozen tissues, although this would have to be determined in larger study sets.

We observed a difference in the optimal cutoff points for HER2 expression between the FFPE surgical and biopsy specimens. Recent reports for some clinically important proteins such as estrogen receptor have revealed substantial differences in the measurement obtained between surgical material and biopsy material (40). Some possible reasons for different results from core and surgical specimens may include differences in sampling because the core biopsy material will have fixed much faster than the surgical material, with the delay in formalin exposure of the center of a surgical specimen resulting in an alternative explanation for this is that the LCM process, which enriches for tumor cells, allows for activated HER2 receptor molecules to be more readily detected within a more homogeneous background. However, the FFPE tissue study set was selected on the basis of highly abundant tumor cells. Because formalin penetrates tissue very slowly (~0.1 mm/h; ref. 36), an alternative explanation for the reduced HER2 phosphorylation in the HER2 FFPE tissue is the loss or degradation of phosphate moieties during the fixation process (37–39) and indicates that pHER2 may be more reliably measured in frozen tissues, although this would have to be determined in larger study sets.

We observed a difference in the optimal cutoff points for HER2 expression between the FFPE surgical and biopsy specimens. Recent reports for some clinically important proteins such as estrogen receptor have revealed substantial differences in the measurement obtained between surgical material and biopsy material (40). Some possible reasons for different results from core and surgical specimens may include differences in sampling because the core biopsy material will have fixed much faster than the surgical material, with the delay in formalin exposure of the center of a surgical specimen resulting in an alternative explanation for this is that the LCM process, which enriches for tumor cells, allows for activated HER2 receptor molecules to be more readily detected within a more homogeneous background. However, the FFPE tissue study set was selected on the basis of highly abundant tumor cells. Because formalin penetrates tissue very slowly (~0.1 mm/h; ref. 36), an alternative explanation for the reduced HER2 phosphorylation in the HER2 FFPE tissue is the loss or degradation of phosphate moieties during the fixation process (37–39) and indicates that pHER2 may be more reliably measured in frozen tissues, although this would have to be determined in larger study sets.
observed in the IHC/FISH result supports the postulate that the HER2 activation number of HER2 total HER2 status. In our FFPE tissues, we found that a functional active network regardless of the underpinning the receptor-directed signaling is transduced and results in a levels seen in the HER2 status of other HER family receptors as well as downstream signaling in tumors from patients who were determined to be HER2/HER2 tumors benefit from trastuzumab (8). It has been speculated that this result could stem from individuals with HER2 primary tumors having circulating tumor cells that are HER2 or that trastuzumab may block other membrane receptor tyrosine kinases or block other pathways acting through AKT even if HER2 is not amplified. We provide an alternative explanation based on the activation status of the HER receptors. Using a quantitative, highly sensitive protein array assay, we identified a subgroup of patients with HER2 breast cancer with levels of activated HER2 comparable with FISH tumors and showed that this activation is coincident with HER3 and EGFR activation and concomitant downstream signaling. This subgroup of patients with breast cancer is not detectable by FISH or IHC, nor identified with intrinsic genomic subtypes or by mRNA expression (data not shown) and is thus excluded from trastuzumab treatment, although these patients may respond to the drug. The activity of trastuzumab can also be affected by the expression of other HER family members as well as the activation of downstream effectors (45, 46). For example, it has been shown that HER3 expression is increased after long-term trastuzumab treatment of HER2 breast cancer cell lines that show primary resistance to trastuzumab (47). In this context, trastuzumab does not inhibit the dimerization of HER2 with other HER receptors such as EGFR and HER3. The monoclonal antibody pertuzumab, which targets the HER2 dimerization domain II and possibly prevents the formation of HER2/HER3 heterodimers (46), may be an alternative therapy option in these instances. On the basis of our results, we believe that retrospective analysis of phosphorylated HER2 levels in tissues from trials such as NSABP B-31, and neoadjuvant therapy trials such as ISPY-2 (www.ispy2.org) where HER2-directed therapies are being evaluated, would be justified.

While we have identified a cohort of tumors from patients with HER2 IHC/FISH breast cancer that appear to have HER2 signaling profiles indistinguishable from IHC/FISH tumors, the true prevalence of this subgroup can only be established in larger study sets. Routine measurement of phosphorylated proteins such as HER2 would require across and between laboratory/platform standardization and control over any pre-analytic variables, such as tissue fixation, that could adversely impact

Our findings could be clinically relevant, as studies from the recent NSABP B-31 adjuvant therapy clinical trial suggest that some patients with breast cancer with HER2 tumors benefit from trastuzumab (8). It has been speculated that this result could stem from individuals with HER2 primary tumors having circulating tumor cells that are HER2 or that trastuzumab may block other membrane receptor tyrosine kinases or block other pathways acting through AKT even if HER2 is not amplified. We provide an alternative explanation based on the activation status of the HER receptors. Using a quantitative, highly sensitive protein array assay, we identified a subgroup of patients with HER2 breast cancer with levels of activated HER2 comparable with FISH tumors and showed that this activation is coincident with HER3 and EGFR activation and concomitant downstream signaling. This subgroup of patients with breast cancer is not detectable by FISH or IHC, nor identified with intrinsic genomic subtypes or by mRNA expression (data not shown) and is thus excluded from trastuzumab treatment, although these patients may respond to the drug. The activity of trastuzumab can also be affected by the expression of other HER family members as well as the activation of downstream effectors (45, 46). For example, it has been shown that HER3 expression is increased after long-term trastuzumab treatment of HER2 breast cancer cell lines that show primary resistance to trastuzumab (47). In this context, trastuzumab does not inhibit the dimerization of HER2 with other HER receptors such as EGFR and HER3. The monoclonal antibody pertuzumab, which targets the HER2 dimerization domain II and possibly prevents the formation of HER2/HER3 heterodimers (46), may be an alternative therapy option in these instances. On the basis of our results, we believe that retrospective analysis of phosphorylated HER2 levels in tissues from trials such as NSABP B-31, and neoadjuvant therapy trials such as ISPY-2 (www.ispy2.org) where HER2-directed therapies are being evaluated, would be justified.

While we have identified a cohort of tumors from patients with HER2 IHC/FISH breast cancer that appear to have HER2 signaling profiles indistinguishable from IHC/FISH tumors, the true prevalence of this subgroup can only be established in larger study sets. Routine measurement of phosphorylated proteins such as HER2 would require across and between laboratory/platform standardization and control over any pre-analytic variables, such as tissue fixation, that could adversely impact
precision and accuracy. Fortunately, new types of tissue fixatives and tissue processing methods (38, 48–50) are being developed specifically to preserve labile analytes in the clinical setting so that the impact of these variables on routine analysis can be more effectively minimized. In the future, clinical trials will be needed to evaluate whether women with breast cancers which are HER2+ but have high levels of pHER2 may benefit clinically from combinations of HER-targeted therapies. Quantitative analysis of the phosphorylation/activation levels of receptor tyrosine kinases, along with the analysis of activation of the linked downstream signal transduction network can potentially identify new patient cohorts that could benefit from molecular targeted inhibitors. Such patients may be missed by current testing methods that measure only the presence or absence of the drug target (e.g., total HER2) and thus, functional signaling analysis may provide new opportunities for personalized therapy if these measurements prove clinically useful.

Disclosure of Potential Conflicts of Interest

J.D. Wulfkuhle, V. Espina, M. Pierobon, L.A. Liotta, and E.F. Petricoin III have ownership interest in Theranostics Health, Inc. A. DeMichael has commercial research grants from Incyte, Pfizer, Genentech, and Millenium. L.A. Liotta and E.F. Petricoin III are on the advisory board of Theranostics Health, Inc. No potential conflicts of interest were disclosed by the other authors.

Disclaimer

The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

References


Authors’ Contributions

Conception and design: J.D. Wulfkuhle, A. DeMichael, L. Isserman, K.F. Becker, E.F. Petricoin III

Development of methodology: J.D. Wulfkuhle, C. Wolff, K. Tran, M. Pierobon, L. Isserman, E.F. Petricoin III

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.D. Wulfkuhle, C. Wolff, R. Langer, K. Tran, J. Illi, V. Espina, A. DeMichael, A. Walch, H. Bronger, I. Becker, C. Waldhöfer, H. Höfler

Analysis and interpretation of data (e.g., statistical analysis, bioinformatics, computational analysis): J.D. Wulfkuhle, D. Berg, C. Wolff, K. Tran, J. Deng, A. DeMichael, A. Walch, L. Isserman, L.A. Liotta, K.-F. Becker, E.F. Petricoin III

Writing, review, and/or revision of the manuscript: J.D. Wulfkuhle, D. Berg, C. Wolff, R. Langer, K. Tran, V. Espina, M. Pierobon, J. Becker, H. Höfler, L. Isserman, L.A. Liotta, K.-F. Becker, E.F. Petricoin III

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K. Tran, A. DeMichael, L. Isserman, E.F. Petricoin III

Study supervision: K.-F. Becker, E.F. Petricoin III

Grant Support

The I-SPY 1 TRIAL (CALGB 150007 and 150012) was supported, in part, by grants from the National Cancer Institute (CA13946) to the Cancer and Leukemia Group B (Monica M. Bertagnolli, MD, Chair) and to the CALGB Statistical Center (Daniel J. Sargent, PhD, CA53601)

This research was also supported by NIH (National Genomeforschungszentrum) Project of the BMFF (Bundesministerium für Bildung und Forschung), Grant 01GK0805 (K.-F. Becker); College of Science, George Mason University (E.F. Petricoin III and L.A. Liotta); Grant #CA53603, University of California, San Francisco (L. Isserman), and the Deutsche Forschungsgemeinschaft WA 1656/3-1 (A. Walch)
HER2 Signaling Activation in IHC/FISH-Negative Breast Tumors


